---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-23-000077"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:53:49.255444+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences to acquire Acclarent from Ethicon for $275M cash plus $5M milestone

## Summary
- Purchase price: $275M in cash at closing, plus $5M regulatory milestone; acquisition of all outstanding shares of Acclarent.
- Acclarent generated ~$110M revenue in 2022 with gross margins in line with Integra's company average.
- Deal expected to close by Q2 2024, subject to HSR clearance, IIA approval, and other customary conditions.
- Acquisition is accretive to Integra's long-range plan and adds ~$1B to CSS total addressable market.
- Acclarent's ENT portfolio (balloon dilation, navigation systems) is adjacent to Integra's neurosurgery business.

## SEC filing metadata
- accession: 0000917520-23-000077
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752023000077/0000917520-23-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752023000077/iart-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-23-000077
- JSON: https://secwatch.observer/filing/0000917520-23-000077.json
- Plain text: https://secwatch.observer/filing/0000917520-23-000077.txt

## Key facts
- Material Agreements
  INTEGRA LIFESCIENCES HOLDINGS CORP entered into Purchase Agreement with Ethicon, Inc. valued at $275.0 million in cash (effective 2023-12-12).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Ethicon, Inc.
  - Value: $275.0 million in cash
  - Effective: 2023-12-12
  source text: On December 12, 2023, Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) between the Company, Integra LifeSciences Israel Ltd., a private company organized under the laws of the State of Israel and a wholly-owned subsidiary of the Company (“Buyer Israeli Sub”), and Ethicon, Inc., a New Jersey corporation (“Seller”), pursuant to which the Company agreed to acquire all of the outstanding common shares (the “Transferred Shares”) of Acclarent, Inc., a Delaware corporation and wholly-owned subsidiary of Seller (“Acclarent”) for $275.0 million in cash, subject to customary purchase price adjustments, and a cash payment of $5.0 million upon the achievement of a regulatory milestone .
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000077/0000917520-23-000077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.